08:00 , Jan 28, 2016 |  BC Innovations  |  Strategy

CIRM's endgame

In the latest effort to make good on promises made to the voters who created the California Institute for Regenerative Medicine (CIRM) in 2004, the agency has approved a strategic plan spelling out concrete goals...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

OpRegen regulatory update

FDA granted Fast Track Designation to OpRegen from Cell Cure to treat dry age-related macular degeneration (AMD). The human embryonic stem cell-derived retinal pigmented epithelial (RPE) cells are in Phase I/IIa testing for geographic atrophy...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

BioTime ophthalmic news

BioTime will purchase 87,456 shares of its Cell Cure NeuroSciences Ltd. subsidiary in exchange for 906,735 BioTime shares at $3.86, or about $3.5 million. The price is a 5.1% premium based BioTime's close on Nov....
07:00 , Oct 25, 2010 |  BC Week In Review  |  Company News

Cell Cure Neurosciences, Teva deal

Cell Cure, a majority-owned subsidiary of BioTime Inc. (NYSE-A:BTX), granted Teva an exclusive option to license exclusive, worldwide rights to develop and commercialize Cell Cure's OpRegen to treat age-related macular degeneration (AMD). OpRegen is a...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Company News

Allon, Amicus Therapeutics, Cell Cure Neurosciences Ltd., Intra-Cellular, Neurocrine, P2D Inc., Proneuron, ReNeuron, Sangamo, Wyeth, Michael J. Fox Foundation F

The foundation awarded the companies a total of $4.6 million in grants for preclinical development of compounds to treat Parkinson's disease (PD). Allon Therapeutics Inc . (TSX:NPC), Vancouver, B.C  Amicus Therapeutics Inc., Cranbury, N.J.  Cell...